The legislation governing medical devices (MDs) having largely demonstrated its ineffectiveness during the PIP implant scandal, the new 2017/745 regulation reinforces patient safety by introducing clinical evaluation of the MD, post-market surveillance and a unique identification system for better traceability is more transparency.

Stéphane ANCEL, Commercial Director at Ackomas, presents Ackomas’ approach and its innovative KOA solution in an exclusive interview with The Pharmaceutical Post magazine.

Two options to access the full interview (P62):

Enjoy your reading!

Was this content helpful?